Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 30;2013(4):CD009084.
doi: 10.1002/14651858.CD009084.pub2.

Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities

Fareez Rana  1 , Aynur Gormez, Susan Varghese
Affiliations

Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities

Fareez Rana et al. Cochrane Database Syst Rev. .

Abstract

Background: Self-injurious behaviour among people with intellectual disability is relatively common and often persistent. Self-injurious behaviour continues to present a challenge to clinicians. It remains poorly understood and difficult to ameliorate despite advances in neurobiology and psychological therapies. There is a strong need for a better evidence base in prescribing and monitoring of drugs in this population, especially since none of the drugs are actually licensed for self-injurious behaviour.

Objectives: To determine clinical effectiveness of pharmacological interventions in management of self-injurious behaviour in adults with intellectual disability.

Search methods: We searched the following databases on 19 February 2012: CENTRAL, MEDLINE, EMBASE, PsycINFO, CINAHL, Science Citation Index, Social Science Citation Index, Conference Proceedings Citation Index - Science, Conference Proceedings Citation Index - Social Science and Humanities, ZETOC and WorldCat. We also searched ClinicalTrials.gov, ICTRP and the reference lists of included trials.

Selection criteria: We included randomised controlled trials that examined drug interventions versus placebo for self-injurious behaviour (SIB) in adults with intellectual disability.

Data collection and analysis: Two review authors independently extracted data and assessed risk of bias for each trial using a data extraction form. We present a narrative summary of the results is presented. We did not consider meta-analysis was appropriate due to differences in study designs, differences between interventions and heterogeneous outcome measures.

Main results: We found five double-blind placebo-controlled trials that met our inclusion criteria. These trials assessed effectiveness and safety of drugs in a total of 50 people with intellectual disability demonstrating SIB. Four trials compared the effects of naltrexone versus placebo and one trial compared clomipramine versus placebo.One of the naltrexone versus placebo trials reported that naltrexone had clinically significant effects (≥ 33% reduction) on the daily rates of three of the four participants' most severe form of SIB and modest to substantial reductions in SIB for all participants; however, this study did not report on statistical significance. Another trial reported that naltrexone attenuated SIB in all four participants, with 25 mg and 50 mg doses producing a statistically significant decrease in SIB (P value < 0.05). Another trial (eight people) indicated that naltrexone administration was associated with significantly fewer days of high frequency self injury and significantly more days with low frequency self injury. Naltrexone had different effects depending on the form and location of self injury. Another trial with only 26 participants found that neither single-dose (100 mg) nor long-term (50 and 150 mg) naltrexone treatment had any therapeutic effect on SIB.Comparison of clomipramine versus placebo found no statistically significant benefit for any outcome measure, which included SIB rate and intensity, stereotypy and adverse events. However, it showed clinically significant improvement in the rate and intensity of SIB and stereotypy.There were very few noteworthy adverse events to report in any of the four trials in which these were reported.All trials were at high risk of bias, apart from one trial (Lewis 1996), which was probably at low risk of bias. The short period of follow-up was a significant drawback in the design of all five trials, as it did not allow long-term assessment of behaviour over time.We were unable to examine the efficacy of antidepressants other than clomipramine, antipsychotics, mood stabilisers or beta-blockers as we did not identify any relevant placebo-controlled trials.

Authors' conclusions: There was weak evidence in included trials that any active drug was more effective than placebo for people with intellectual disability demonstrating SIB. Due to sparse data, an absence of power and statistical significance, and high risk of bias for four of the included trials, we are unable to reach any definite conclusions about the relative benefits of naltrexone or clomipramine compared to placebo.

PubMed Disclaimer

Conflict of interest statement

  1. Aynur Gormez ‐ none known

  2. Fareez Rana ‐ none known

  3. Susan Varghese ‐ none known

Figures

1
1
Study flow diagram
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Lewis 1996 {published data only (unpublished sought but not used)}
    1. Lewis M, Bodfish J, Powell S, Parker D, Golden R. Clomipramine treatment for self‐injurious behaviour of individuals with mental retardation: a double‐blind comparison with placebo. American Journal on Mental Retardation 1996;100(6):654‐65. - PubMed
Sandman 1990 {published data only}
    1. Sandman CA, Barron JL, Colman H. An orally administered opiate blocker, naltrexone, attenuates self‐injurious behavior. American Journal on Mental Retardation 1990;95(1):93‐102. - PubMed
Symons 2001 {published data only}
    1. Symons F, Wulfsberg A, Sutton K, Tapp J, Heeth W, Bodfish W. Sequential analysis of the effects of naltrexone on the environmental mediation of self injurious behaviour. Experimental and Clinical Psychopharmacology 2001;9:269‐76. - PubMed
Thompson 1994 {published data only}
    1. Thompson T, Hackenberg T, Cerutti D, Baker D, Axtell S. Opioid antagonist effects on self‐injury in adults with mental retardation: response form and location as determinants of medication effects. American Journal on Mental Retardation 1994;99(1):85‐102. - PubMed
Willemsen‐Swinkels 1995 {published and unpublished data}
    1. Willemsen‐Swinkels S, Buitelaar J, Nijhof G, Engeland H. Failure of naltrexone hydrochloride to reduce self injurious and autistic behaviour in mentally retarded adults. Archives General Psychiatry 1995;52:766‐73. - PubMed

References to studies excluded from this review

Bodfish 1997 {published data only}
    1. Bodfish J, McCuller W, Madison J, Register M, Mailman R, Lewis M. Placebo, double‐blind evaluation of long‐term naltrexone treatment effects for adults with mental retardation and self‐injury. Journal of Developmental and Physical Disabilities 1997;9(2):135‐52.
Garcia 1999 {published data only}
    1. Garcia D, Smith G. Using analog baselines to assess the effects of naltrexone on self‐injurious behaviour. Research in Developmental Disabilities 1999;20(1):1‐21. - PubMed
Kars 1990 {published data only}
    1. Kars H, Broekema W, Glaudemans‐van Gelderen I, Verhoeven WMA, Ree JM. Naltrexone attenuates self‐injurious behaviour in mentally retarded subjects. Biological Psychiatry 1990;27:741‐6. - PubMed
Sandman 1983 {published data only}
    1. Sandman C, Datta P, Barron J, Hoehler F, Williams C, Swanson J. Naloxone attenuates self‐abusive behaviour in developmentally disabled clients. Applied Research in Mental Retardation 1983;4:5‐11. - PubMed
Szymanski 1987 {published data only}
    1. Szymanski L, Kedesdy J, Sulkes S, Cutler A. Naltrexone in treatment of self injurious behaviour: a clinical study. Research in Developmental Disabilities 1987;8:179‐90. - PubMed
Zingarelli 1992 {published data only}
    1. Zingarelli G, Ellman G, Wymore A, Heldron S, Chicz‐Demet A. Clinical effects of naltrexone on autistic behaviour. American Journal on Mental Retardation 1992;97(1):57‐63. - PubMed

Additional references

Alexander 2003
    1. Alexander R. Diagnosis of personality disorders in learning disability. The British Journal of Psychiatry 2003;182:s28‐31. - PubMed
Aman 1985
    1. Aman MG, Singh NN, Stewart AW, Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency 1985;89(5):485‐91. - PubMed
Aman 1993
    1. Aman M. Efficacy of psychotropic drugs for reducing self‐injurious behavior in the developmental disabilities. Annals of Clinical Psychiatry 1993;5(3):171‐88. - PubMed
Beail 2007
    1. Beail N. Staff Emotional Reactions to Service User Self Injury. Changing Practice Reducing the Risk. BILD Conference. 2007.
Bhaumik 2005
    1. Bhaumik S, Branford D (editors). Chapter 5: Self‐injurious behaviour. The Frith Prescribing Guidelines for Adults with Learning Disability. Abingdon, UK: Taylor & Francis, 2005:45.
Bhaumik 2010
    1. Bhaumik S, Tyrer F, Barrett M, Tin N, McGrother CW, Kiani R. The relationship between carers report of autistic traits and clinical diagnoses of autism spectrum disorders in adults with intellectual disability. Research in Developmental Disabilities 2010;31(3):705‐12. - PubMed
BNF 2010
    1. Royal Pharmaceutical Society and British Medical Association. British National Formulary. Basingstoke, UK: British Medical Journal Group and Pharmaceutical Press, 2010.
Borthwick‐Duffy 1994
    1. Borthwick‐Duffy SA. Prevalence of destructive behaviors: a study of aggression, self‐injury and property destruction. In: Thompson T, Gray D editor(s). Destructive Behaviour in Developmental Disabilities: Diagnosis and Treatment. Thousand Oaks, CA: Sage Publications, 1994:3‐23.
Breese 1995
    1. Breese GR, Criswell HE, Duncan GE, Moy SS, Johnson KB, Wong DF, et al. Model for reduced brain dopamine in Lesch‐Nyhan syndrome and the mentally retarded: neurobiology of neonatal‐6‐hydroxydopamine‐lesioned rats. Mental Retardation and Developmental Disabilities Research Reviews 1995;1(2):111‐9.
Chadsey‐Rusch 1989
    1. Chadsey‐Rusch J, Sprague RL. Maladaptive behaviours associated with neuroleptic drug maintenance. American Journal on Mental Retardation 1989;93:607‐17. - PubMed
Collacott 1998
    1. Collacott RA, Cooper SA, Branford D, McGrother C. Epidemiology of self‐injurious behaviour in adults with learning disabilities. The British Journal of Psychiatry 1998;173(5):428‐32. - PubMed
Conners 1969
    1. Conners CK. A teacher rating scale for use in drug studies with children. American Journal of Psychiatry 1969;126:884‐8. - PubMed
Cooper 2009
    1. Cooper SA, Smiley E, Allan LM, Jackson A, Finlayson J, Mantry D. Adults with intellectual disabilities: prevalence, incidence and remission of self‐injurious behaviour, and related factors. Journal of Intellectual Disability Research 2009;53(3):200‐16. - PubMed
Davanzo 1996
    1. Davanzo PA, King BH. Open trial lamotrigine in the treatment of self‐injurious behavior in an adolescent with profound mental retardation. Journal of Child and Adolescent Psychopharmacology 1996;6(4):273‐9. - PubMed
DC‐LD 2001
    1. Royal College of Psychiatrists. Diagnostic Criteria For Psychiatric Disorders For Use With Adults With Learning Disabilities/Mental Retardation. London: Gaskell Press, 2001.
Deb 2007
    1. Deb S, Unwin GL. Psychotropic medication for behavior problems in people with intellectual disability: a review of the current literature. Current Opinion in Psychiatry 2007;20(5):461‐6. - PubMed
Einfeld 2001
    1. Einfeld SL. Systematic management approach to pharmacotherapy for people with learning disabilities. Advances in Psychiatric Treatment 2001;7(1):43‐9.
Elbourne 2002
    1. Elbournea DR, Altmanb DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
Emerson 1995
    1. Emerson E, Bromley J. The form and function of challenging behaviours. Journal of Intellectual Disability Research 1995;39:388‐98. - PubMed
Emerson 2001
    1. Emerson E, Kiernan C, Alborz A, Reeves D, Mason H, Swarbrick R, et al. The prevalence of challenging behaviors: a total population study. Research in Developmental Disabilities 2001;22:77‐93. - PubMed
Emerson 2001a
    1. Emerson E. Challenging behaviour: analysis and intervention in people with severe intellectual disabilities. Cambridge, UK: Cambridge University Press, 2001.
Fee 1992
    1. Fee VE, Matson JL. Definition, classification, and taxonomy. In: J. K. Luiselli, J. L. Matson, N. N. Singh editor(s). Self‐Injurious Behavior: Analysis, Assessment, And Treatment. New York: Springer‐Verlag, 1992:3‐20.
Follman 1992
    1. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992;45(7):769‐73. - PubMed
Gates 1996
    1. Gates B, Wray J, Newell R. Challenging behaviour in children with learning disabilities. British Journal of Nursing 1996;5(19):1189‐94. - PubMed
Gates 2007
    1. Gates B. Chapter 21: Theory and practice of managing self injurious behaviour in people with learning disabilities. In: Gates B editor(s). Learning Disabilities: Toward Inclusion. 5th Edition. Churchill Livingstone, 2007:445‐58.
Griffin 1986
    1. Griffin JC, Williams DE, Stark MT, Altmeyer BK, Mason M. Self‐injurious behavior: a state‐wide prevalence survey of the extent and circumstances. Applied Research in Mental Retardation 1986;7(1):105‐16. - PubMed
Hammock 1995
    1. Hammock RG, Schroeder SR, Levine WR. The effect of clozapine on self‐injurious behavior. Journal of Autism and Developmental Disorders 1995;25(6):611‐26. - PubMed
Hammock 2001
    1. Hammock R, Levine WR, Schroeder SR. Brief report: effects of clozapine on self‐injurious behaviour of two risperidone nonresponders with mental retardation. Journal of Autism and Developmental Disorders 2001;31(1):109‐13. - PubMed
Herman 1989
    1. Herman BH, Hammock MK, Egan J, Arthur‐Smith A, Chatoor I, Werner A. Role for opioid peptides in self‐injurious behavior: dissociation from autonomic nervous system functioning. Developmental Pharmacology and Therapeutics 1989;12(2):81‐9. - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, 2008.
Hillery 2007
    1. Hillery J, Dodd P. Self injurious behaviour. In: Bouras N, Holt G editor(s). Psychiatric and Behavioural Disorders in Intellectual and Developmental Disabilities. 2nd Edition. Cambridge: Cambridge University Press, 2007:225‐37.
Horrocks 2003
    1. Horrocks J, Price S, House A, Owens D. Self‐injury attendances in the accident and emergency department. Clinical database study. British Journal of Psychiatry 2003;183:34‐9. - PubMed
Johnny 2009
    1. Johnny M, Daniene N. Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: an overview. Research in Developmental Disabilities 2009;30(3):572‐86. - PubMed
Kahng 2002
    1. Kahng S, Iawata BA, Lewin AB. Behavioural treatment of self‐injury. American Journal of Mental Retardation 2002;107(3):212‐21. - PubMed
Kemp 2008
    1. Kemp AS, Fillmore PT, Lenjavi MR, Lyon M, Chicz‐Demet A, Touchette PE, et al. Temporal patterns of self‐injurious behavior correlate with stress hormone levels in the developmentally disabled. Psychiatry Research 2008;157(1):181‐9. - PMC - PubMed
Lakin 1983
    1. Lakin KC, Hill BK, Hauber FA, Bruininks RH, Heal IW. New admissions and readmissions to a national sample of public residential facilities. American Journal of Mental Deficiency 1983;88(1):13‐20. - PubMed
Lefebvre 2008
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, 2008:95‐150.
Lewis 1996a
    1. Lewis MH. Brief report: psychopharmacology of autism spectrum disorders. Journal of Autism and Developmental Disorders 1996;26(2):231‐5. - PubMed
Lewis 2001
    1. Lewis S, Clarke M. Trying to see the wood and the trees. BMJ 2001;322:1479‐80. - PMC - PubMed
Matson 2000
    1. Matson JL, Bamburg JW, Mayville EA, Pinkston J, Bielecki J, Kuhn D, et al. Psychopharmacology and mental retardation: a 10 year review (1990‐1999). Research in Developmental Disabilities 2000;21:263‐96. - PubMed
Maurice 1982
    1. Maurice P, Trudel G. Injurious behavior prevalence and relationships to environmental events. In: Hollis JH editor(s). Life‐Threatening Behavior: Analysis And Intervention. Washington, DC: American Association on Mental Retardation, 1982:81‐103. - PubMed
McDonough 2000
    1. McDonough M, Hillery J, Kennedy N. Olanzapine for chronic, stereotypic self‐injurious behaviour: a pilot study in seven adults with intellectual disability. Journal of Intellectual Disability Research 2000;44(6):677‐84. - PubMed
Mikkelson 1986
    1. Mikkelson EJ. Low dose haloperidol for stereotypic self‐injurious behaviour in mentally retarded. New England Journal of Medicine 1986;316(6):398‐9. - PubMed
Murphy 1985
    1. Murphy G, Wilson B. Self‐Injurious Behaviour. Kidderminster, UK: British Institute of Mental Handicap Publications, 1985:15.
Murphy 1993
    1. Murphy G, Oliver C, Corbett J. Epidemiology of self‐injury, characteristics of people with severe self‐injury and initial treatment outcome. Research To Practice? Implications Of Research On The Challenging Behaviour Of People With Learning Disability. Kidderminster, UK: British Institute of Learning Disabilities, 1993.
Murphy 1999
    1. Murphy G. Self‐injurious behaviour: what do we know and where are we going. Tizard Learning Disability Review 1999;4(1):5‐12.
National Institute of Mental Health 1985
    1. National Institute of Mental Health. Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacology Bulletin 1985; Vol. 21:830‐42. - PubMed
Prangnell 2010
    1. Prangnell SJ. Behavioural interventions for self injurious behaviour: a review of recent evidence. British Journal of Learning Disabilities 2010;38(4):259‐70.
Quine 1985
    1. Quine L, Pahl J. Examining the causes of stress in families with severely mentally handicapped children. British Journal of Social Work 1985;15:501‐17.
Rapoport 1985
    1. Rapoport JL, Conners CK, Reating N. Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacology Bulletin 1985;21(4):1073‐75. - PubMed
Read 2007
    1. Read SG, Rendall M. An open‐label study of risperidone in the improvement of quality of life and treatment of symptoms of violent and self‐injurious behaviour in adults with intellectual disability. Journal of Intellectual Disability Research 2007;20(3):256‐64.
Rojahn 2002
    1. Rojahn J, Esbensen AJ. Epidemiology of self‐injurious behavior in mental retardation: a review. In: Schroeder SR, Oster‐Granite ML, Thompson T editor(s). Self‐Injurious Behavior: Gene‐Brain‐Behavior Relationships. Washington DC: American Psychological Association, 2002:41‐77.
Rojahn 2007
    1. Rojahn J, Shroeder SR, Hoch TA. Self‐injurious behaviour in intellectual disabilities. 1st Edition. Vol. 2, Amsterdam, The Netherlands: Elsevier, 2007.
Ruedrich 1999
    1. Ruedrich S, Swales TP, Fossaceca C, Toliver J, Rutkowski A. Effect of divalproex sodium on aggression and self‐injurious behaviour in adults with intellectual disability: a retrospective review. Journal of Intellectual Disability Research 1999;43(2):105‐11. - PubMed
Ruedrich 2008
    1. Ruedrich SL, Swales TP, Rossvanes C, Diana L, Arkadiev V, Lim K. Atypical antipsychotic medication improves aggression, but not self‐injurious behaviour, in adults with intellectual disabilities. Journal of Applied Research In Intellectual Disabilities 2008;52(2):132‐40. - PubMed
Saemundsen 2010
    1. Saemundsen E, Juliusson H, Hjaltested S, Gunnarsdottir T, Halldorsdottir T, Hreidarsson S. Prevalence of autism in an urban population of adults with severe intellectual disabilities ‐ a preliminary study. Journal of Intellectual Disability Research 2010;54(8):727‐35. - PubMed
Sandman 2008
    1. Sandman CA, Touchette PE, Marion SD, Chicz‐DeMet A. The role of proopiomelanocortin (POMC) in sequentially dependent self‐injurious behavior. Developmental Psychobiology 2008;50(7):680‐9. - PMC - PubMed
Sohanpal 2007
    1. Sohanpal SK, Deb S, Thomas C, Soni R, Lenotre L, Unwin G. The effectiveness of antidepressant medication in the management of behaviour problems in adults with intellectual disabilities: a systematic review. Journal of Intellectual Disability Research 2007;51(Pt 10):750‐65. - PubMed
Sparrow 1984
    1. Sparrow SS, Balla DA, Cicchetti DV. Vineland Adaptive Behaviour Scales. American Guidance Service 1984.
Symons 2004
    1. Symons FJ, Thompson A, Rodriguez MC. Self ‐injurious behaviour and the efficacy of naltrexone treatment: a quantitative synthesis. Mental Retardation and Developmental Disabilities Research Reviews 2004;10(3):193‐200. - PubMed
Symons 2011
    1. Symons FJ. Self‐injurious behavior in neurodevelopmental disorders: relevance of nociceptive and immune mechanisms. Neuroscience & Biobehavioral Reviews 2011;35(5):1266‐74. - PMC - PubMed
Taylor 2010
    1. Taylor L, Oliver C, Murphy G. The chronicity of self‐injurious behaviour: a long‐term follow‐up of a total population study. Journal of Applied Research In Intellectual Disabilities 2011;24(2):105‐17.
Totsika 2008
    1. Totsika V, Toogood S, Hastings RP, Lewis S. Persistence of challenging behaviours in adults with intellectual disability over a period of 11 years. Journal of Intellectual Disability Research 2008;5(Pt 5):446‐57. - PubMed
Villalba 2000
    1. Villalba R, Harrington CJ. Repetitive self‐injurious behaviour: a neuropsychiatric perspective and review of pharmacologic treatments. Seminars in Clinical Neuropsychiatry 2000;5(4):215‐26. - PubMed
WHO 1992
    1. World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders. Geneva: WHO, 1992:226‐31.
Wieseler 1995
    1. Wieseler NA, Hanson RH, Nord G. Investigation of mortality and morbidity associated with self‐injurious behaviour. American Journal on Mental Retardation 1995;100(1):1‐5. - PubMed
Winchel 1991
    1. Winchel RM, Stanley M. Self‐injurious behavior: a review of the behavior and biology of self‐mutilation. The American Journal of Psychiatry 1991;148(3):306‐17. - PubMed
Yaryura‐Tobias 1999
    1. Yaryura‐Tobias JA, Mancebo MC, Neziroglu FA. Clinical and theoretical issues in self‐injurious behaviour. Revista Brasileira de Psiquiatria 1999;21(3):178‐83.

Publication types

MeSH terms